Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates

Go back to Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates
(NASDAQ: ADAG) Delayed: 2.41 -0.03 (1.23%)
Previous Close $2.44    52 Week High $ 
Open $2.43    52 Week Low $ 
Day High $2.57    P/E N/A 
Day Low $2.30    EPS $ 
Volume 167,167